Current and Potential Therapies Targeting Inflammation in NASH

被引：31

作者：

Albhaisi, Somaya ^{[1
]}

Noureddin, Mazen ^{[2
]}

机构：

[1] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA

[2] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Karsh Div Gastroenterol & Hepatol, Los Angeles, CA 90048 USA

来源：

FRONTIERS IN ENDOCRINOLOGY | 2021年 / 12卷

关键词：

non-alcoholic steatohepatitis; inflammation; treatment; macrophages; lymphocytes; cytokines; hepatocellular injury; oxidative stress; FATTY LIVER-DISEASE; NONALCOHOLIC STEATOHEPATITIS PATIENTS; FARNESOID X RECEPTOR; EXTRACELLULAR VESICLES; S-ADENOSYLMETHIONINE; DIAGNOSTIC-ACCURACY; HEPATIC STEATOSIS; NATURAL-HISTORY; VITAMIN-D; FIBROSIS;

D O I：

10.3389/fendo.2021.767314

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease (NAFLD). It is characterized by hepatic steatosis, inflammation, hepatocellular injury, and fibrosis. Inflammation plays a key role in the progression of NASH and can be provoked by intrahepatic (e.g., lipotoxicity, immune responses, oxidative stress and cell death) and extrahepatic sources (adipose tissue or gut). The identification of triggers of inflammation is central to understanding the mechanisms in NASH development and progression and in designing targeted therapies that can halt or reverse the disease. In this review, we summarize the current and potential therapies targeting inflammation in NASH.

引用

收藏

页数：8

相关论文

共 50 条

[31] Triggering and resolution of inflammation in NASH [J].

Schuster, Susanne ;

Cabrera, Daniel ;

Arrese, Marco ;

Feldstein, Ariel E. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2018, 15 (06) :349-364

[32] SOD1-targeting therapies for neurodegenerative diseases: a review of current findings and future potential [J].

Franklin, John P. ;

Azzouz, Mimoun ;

Shaw, Pamela J. .

EXPERT OPINION ON ORPHAN DRUGS, 2020, 8 (10) :379-392

[33] Anti-diabetic drugs and NASH: from current options to promising perspectives [J].

Smati, Sarra ;

Canivet, Clemence M. ;

Boursier, Jerome ;

Cariou, Bertrand .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (08) :813-825

[34] Butyrolactone I attenuates inflammation in murine NASH by inhibiting the NF-KB signaling pathway [J].

Tian-qi, Chen ;

Yan-fang, Deng ;

Yan-yan, Wang ;

Yong-hui, Zhang .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 626 :167-174

[35] Therapeutic potential of targeting mixed lineage kinases in cancer and inflammation [J].

Gallo, Kathleen A. ;

Ellsworth, Edmund ;

Stoub, Hayden ;

Conrad, Susan E. .

PHARMACOLOGY & THERAPEUTICS, 2020, 207

[36] Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis [J].

Satiya, Jinendra ;

Snyder, Heather S. ;

Singh, Shivaram Prasad ;

Satapathy, Sanjaya K. .

TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 6

[37] Pathogenesis from Inflammation to Cancer in NASH-Derived HCC [J].

Yu, Simiao ;

Wang, Jingxiao ;

Zheng, Haocheng ;

Wang, Ruilin ;

Johnson, Nadia ;

Li, Tao ;

Li, Ping ;

Lin, Jie ;

Li, Yuan ;

Yan, Jin ;

Zhang, Ying ;

Zhu, Zhenyu ;

Ding, Xia .

JOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 :855-867

[38] Ameliorative role of bioactive phytoconstituents targeting obesity associated NAFLD by modulation of inflammation and lipogenesis pathways: a comprehensive review [J].

Barbhuiya, Pervej Alom ;

Sen, Saikat ;

Pathak, Manash Pratim .

PHYTOCHEMISTRY REVIEWS, 2024, 23 (04) :969-996

[39] TLR9 in MAFLD and NASH: At the Intersection of Inflammation and Metabolism [J].

Shepard, Christopher R. .

FRONTIERS IN ENDOCRINOLOGY, 2021, 11

[40] Molecular docking targeting autophagy pathway mediate abrogation of NASH by specific functional foods: update review [J].

Mohamed, Merehan Alaa-ElDin. ;

Rihan, Shaimaa ;

Elbakry, Mustafa M. M. ;

Moselhy, Said S. .

NATURAL PRODUCT RESEARCH, 2025, 39 (04) :864-887

← 1 2 3 4 5 →